After Troy Burklund had implant surgery on his right hip four years ago, he looked forward to feeling better and being more mobile. Instead, the Sauk Rapids, Minn., police officer was plunged into a nightmare of frustration and pain that forced him to retire early.
"A lot of mornings I wake up and wonder what I'm going to do," said Burklund, now 53. "My life has been on hold and in pain since 2010."
He doesn't blame his surgeon, who trusted Michigan medical manufacturer Stryker Orthopedic's claim that its new two-piece hip-replacement device adapted more easily to a person's body shape, lasted longer than traditional implants and was better for younger patients. But he does blame Stryker.
The first suit over the defective device quietly landed in a New Jersey courthouse more than two years ago. Soon, however, the fight for Burklund and thousands more shifted to Minneapolis, where a select group of attorneys helped craft a $1.425 billion settlement.
Last year, attorney Genevieve Zimmerman successfully petitioned a judicial panel to consolidate the more than 4,500 state and federal lawsuits against Stryker and its subsidiary and bring the legal battle to Minnesota. In an unusually short time, the plaintiffs defeated a medical technology giant that had sold doctors a toxic product that literally corroded away inside patients.
Stryker's deal is the second multibillion-dollar settlement over flawed hip-replacement equipment in the past year. Johnson & Johnson is expected to pay more than $3 billion to satisfy at least 8,000 suits. But unlike most recalled products, Stryker's Rejuvenate and ABG II modular-neck implants will have a nearly 100 percent failure rate, said Meshbesher & Spence attorney Tony Nemo.
In addition to a provision that allows patients to be compensated for a second surgery to remove the faulty device, the settlement is unprecedented because the amount Stryker will pay out is uncapped. Zimmerman, one of six attorneys appointed to shepherd the negotiations, said it may be the first uncapped deal involving a recalled medical or pharmaceutical product.
"I feel lucky that I can do good for people," said Zimmerman, who has devoted three years to the case. "The money can't put them the way they were before the surgeries, but it will make a difference in their lives."